Entropy Technologies LP Has $441,000 Position in Evolent Health, Inc. (NYSE:EVH)

Entropy Technologies LP raised its holdings in Evolent Health, Inc. (NYSE:EVH - Free Report) by 247.6% during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 39,219 shares of the technology company's stock after buying an additional 27,936 shares during the period. Entropy Technologies LP's holdings in Evolent Health were worth $441,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently bought and sold shares of EVH. R Squared Ltd bought a new stake in Evolent Health in the fourth quarter valued at approximately $31,000. Covestor Ltd increased its stake in shares of Evolent Health by 138.1% during the third quarter. Covestor Ltd now owns 1,424 shares of the technology company's stock worth $40,000 after purchasing an additional 826 shares during the period. GAMMA Investing LLC increased its stake in shares of Evolent Health by 5,365.5% during the third quarter. GAMMA Investing LLC now owns 1,585 shares of the technology company's stock worth $45,000 after purchasing an additional 1,556 shares during the period. KBC Group NV increased its stake in shares of Evolent Health by 124.6% during the fourth quarter. KBC Group NV now owns 6,741 shares of the technology company's stock worth $76,000 after purchasing an additional 3,739 shares during the period. Finally, Dynamic Advisor Solutions LLC bought a new position in shares of Evolent Health during the fourth quarter worth approximately $134,000.

Evolent Health Price Performance

Shares of EVH traded up $0.10 during midday trading on Friday, hitting $10.07. The company's stock had a trading volume of 1,745,560 shares, compared to its average volume of 2,244,315. Evolent Health, Inc. has a one year low of $9.45 and a one year high of $35.00. The company's fifty day simple moving average is $10.86 and its two-hundred day simple moving average is $19.22. The company has a quick ratio of 1.04, a current ratio of 1.04 and a debt-to-equity ratio of 0.58. The stock has a market capitalization of $1.17 billion, a price-to-earnings ratio of -11.06 and a beta of 1.45.

Analyst Upgrades and Downgrades

A number of brokerages have recently weighed in on EVH. Citigroup lowered their target price on Evolent Health from $21.00 to $18.00 and set a "buy" rating on the stock in a research note on Friday, January 10th. Truist Financial lowered their target price on Evolent Health from $20.00 to $15.00 and set a "buy" rating on the stock in a research note on Wednesday, January 22nd. Needham & Company LLC reiterated a "buy" rating and set a $15.00 target price on shares of Evolent Health in a research note on Wednesday. Stephens lowered their target price on Evolent Health from $16.00 to $12.00 and set an "equal weight" rating on the stock in a research note on Tuesday, January 21st. Finally, JPMorgan Chase & Co. lowered their price objective on Evolent Health from $15.00 to $13.00 and set an "overweight" rating on the stock in a research note on Tuesday, January 28th. One investment analyst has rated the stock with a hold rating, eleven have issued a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the company has a consensus rating of "Buy" and an average price target of $17.92.

About Evolent Health

Evolent Health, Inc, through its subsidiary, Evolent Health LLC, offers specialty care management services in oncology, cardiology, and musculoskeletal markets in the United States. The company provides platform for health plan administration and value-based business infrastructure. It offers administrative services, such as health plan services, pharmacy benefits management, risk management, analytics and reporting, and leadership and management; and Identifi, a proprietary technology system that aggregates and analyzes data, manages care workflows, and engages patients.